BlossomHill Therapeutics, Inc. - Common Stock, $0.0001 par value per share (BLSM)

CUSIP: 095130100

Q3 2026 13F Holders as of 30 Sep 2026

Holder snapshot 5 signals
Share change
+14,052,056
SEC-reported price per share
$18.64
Indexed holders
26
Value change
+$261,872,338
Number of buys
25
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
31,785,104

Security key

095130100

Report period

Q3 2026

Indexed institutions

26

Top holders

10

Ownership snapshot

Top reported holders of BLSM - BlossomHill Therapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Jingrong Jean Cui
Disclosed value leader
Jingrong Jean Cui
Comparable rows
6/15
Latest evidence
30 Sep 2026
13D/G 3/4/5 Lead comparable stake: 12% 9 rows are not safely comparable across share classes. 13D/G row: Jingrong Jean Cui Showing 1-6 of 15 holder rows.

Quick read

Jingrong Jean Cui leads the comparable SEC ownership view at 12%.

6 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Jingrong Jean Cui's linked filing trail.
Comparable ownership Top 5
Jingrong Jean Cui 12%
Cormorant Asset Management, LP 12%
ORBIMED ADVISORS LLC 8.9%
Janus Henderson Group Ltd. 7.8%
PERCEPTIVE ADVISORS LLC 5.9%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Jingrong Jean Cui
13D/G 3/4/5
President and CEO, Director, 10%+ Owner
12%
Reported 13D/G · 30 Sep 2026
$57,213,187
3,973,138 shares
$0 30 Sep 2026
Cormorant Asset Management, LP
3/4/5 13D/G
10%+ Owner · Chen Bihua
12%
Reported 13D/G · 06 Aug 2026
—
3,637,938 shares
mixed-class rows
— 06 Aug 2026
ORBIMED ADVISORS LLC
3/4/5 13D/G
Director
8.9%
Reported 13D/G · 10 Aug 2026
—
2,714,279 shares
— 10 Aug 2026
Janus Henderson Group Ltd.
13D/G
7.8%
Reported 13D/G · 30 Sep 2026
$46,066,039
2,471,354 shares
$0 30 Sep 2026
PERCEPTIVE ADVISORS LLC
13D/G
5.9%
Reported 13D/G · 07 Aug 2026
—
1,808,533 shares
$0 07 Aug 2026
Vivo Innovation Fund II Holdings, L.P.
13D/G
4.7%
Reported 13D/G · 30 Sep 2026
$27,843,314
1,493,740 shares
-$3,495,000 30 Sep 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
26
Shares
14,102,056
Indexed holders
26
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q3 2026 vs Q2 2026 Across Filers

Q2 2026 indexed holders
—
Q3 2026 indexed holders
26
Indexed holder difference
—
Investor Q2 2026 Shares Q3 2026 Shares Share Diff Share Chg % Q2 2026 value Q3 2026 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .